Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.
1992
n/a
LTM Revenue $432M
LTM EBITDA $132M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of September 2025, BioKangtai reported last 12-month revenue of $432M and EBITDA of $132M.
In the same period, BioKangtai generated $354M in LTM gross profit and $32.9M in net income.
See BioKangtai valuation multiples based on analyst estimatesIn the most recent fiscal year, BioKangtai reported revenue of $372M and EBITDA of $82.9M.
BioKangtai expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See BioKangtai valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $432M | XXX | $372M | XXX | XXX | XXX |
Gross Profit | $354M | XXX | $305M | XXX | XXX | XXX |
Gross Margin | 82% | XXX | 82% | XXX | XXX | XXX |
EBITDA | $132M | XXX | $82.9M | XXX | XXX | XXX |
EBITDA Margin | 31% | XXX | 22% | XXX | XXX | XXX |
EBIT | $47.4M | XXX | $66.6M | XXX | XXX | XXX |
EBIT Margin | 11% | XXX | 18% | XXX | XXX | XXX |
Net Profit | $32.9M | XXX | $28.3M | XXX | XXX | XXX |
Net Margin | 8% | XXX | 8% | XXX | XXX | XXX |
Net Debt | XXX | XXX | $195M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioKangtai has current market cap of CNY 18.6B (or $2.6B), and EV of CNY 20.2B (or $2.8B).
As of October 17, 2025, BioKangtai's stock price is CNY 17 (or $2).
See BioKangtai trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$2.8B | $2.6B | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialBioKangtai's trades at 7.6x EV/Revenue multiple, and 34.2x EV/EBITDA.
See valuation multiples for BioKangtai and 15K+ public compsAs of October 17, 2025, BioKangtai has market cap of $2.6B and EV of $2.8B.
Equity research analysts estimate BioKangtai's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioKangtai has a P/E ratio of 79.4x.
LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $2.6B | XXX | $2.6B | XXX | XXX | XXX |
EV (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
EV/Revenue | 6.6x | XXX | 7.6x | XXX | XXX | XXX |
EV/EBITDA | 21.6x | XXX | 34.2x | XXX | XXX | XXX |
EV/EBIT | 59.9x | XXX | 42.6x | XXX | XXX | XXX |
EV/Gross Profit | 8.0x | XXX | n/a | XXX | XXX | XXX |
P/E | 79.4x | XXX | 92.2x | XXX | XXX | XXX |
EV/FCF | 144.6x | XXX | 154.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioKangtai's last 12 month revenue growth is 15%
BioKangtai's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
BioKangtai's rule of 40 is 51% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioKangtai's rule of X is 67% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioKangtai and other 15K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 15% | XXX | 17% | XXX | XXX | XXX |
EBITDA Margin | 31% | XXX | 22% | XXX | XXX | XXX |
EBITDA Growth | 15% | XXX | -11% | XXX | XXX | XXX |
Rule of 40 | 51% | XXX | 37% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | 67% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
CSL | XXX | XXX | XXX | XXX | XXX | XXX |
Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioKangtai acquired XXX companies to date.
Last acquisition by BioKangtai was XXXXXXXX, XXXXX XXXXX XXXXXX . BioKangtai acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free TrialWhen was BioKangtai founded? | BioKangtai was founded in 1992. |
Where is BioKangtai headquartered? | BioKangtai is headquartered in China. |
Is BioKangtai publicy listed? | Yes, BioKangtai is a public company listed on SHE. |
What is the stock symbol of BioKangtai? | BioKangtai trades under 300601 ticker. |
When did BioKangtai go public? | BioKangtai went public in 2017. |
Who are competitors of BioKangtai? | Similar companies to BioKangtai include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
What is the current market cap of BioKangtai? | BioKangtai's current market cap is $2.6B |
What is the current revenue of BioKangtai? | BioKangtai's last 12 months revenue is $432M. |
What is the current revenue growth of BioKangtai? | BioKangtai revenue growth (NTM/LTM) is 15%. |
What is the current EV/Revenue multiple of BioKangtai? | Current revenue multiple of BioKangtai is 6.6x. |
Is BioKangtai profitable? | Yes, BioKangtai is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of BioKangtai? | BioKangtai's last 12 months EBITDA is $132M. |
What is BioKangtai's EBITDA margin? | BioKangtai's last 12 months EBITDA margin is 31%. |
What is the current EV/EBITDA multiple of BioKangtai? | Current EBITDA multiple of BioKangtai is 21.6x. |
What is the current FCF of BioKangtai? | BioKangtai's last 12 months FCF is $19.6M. |
What is BioKangtai's FCF margin? | BioKangtai's last 12 months FCF margin is 5%. |
What is the current EV/FCF multiple of BioKangtai? | Current FCF multiple of BioKangtai is 144.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.